Skip to ContentSkip to Navigation
About us Latest news Press information

Haisma, Prof. Hidde

Hidde Haisma
Hidde Haisma

Hidde J. Haisma (1957) is professor of Pharmaceutic Gene Modulation at the Pharmacy department of the Faculty of Science and Engineering. He studied medical biology at Utrecht University and has worked in the US (including at Harvard Medical School) and at VU University Amsterdam. In 2000 he was appointed Professor of Pharmaceutic Gene Modulation at the University of Groningen.

Haisma conducts research into the development of drugs that can influence human genes in order to cure diseases. Haisma is editor of a number of journals in the field of gene therapy and has written over 100 publications and various patent applications in his field of study. Haisma is a board member of the Nederlandse Vereniging voor Gen- en Celtherapie (Dutch Society for Gene and Cell Therapy) and of the European Society of Gene and Cell Therapy. He is also a member of the Gene Doping Expert Group of the World Anti-Doping Agency (WADA). October 2016 he received a 100,000 US dollar grant from the WADA for his research project that will focus on the development of a gene doping detection assay based on next generation sequencing.


Previously in the news

Article NOS
Article NOS

Contact and further information

See profile page



Diaz Arguello, O. A., & Haisma, H. J. (2021). Apoptosis-Inducing TNF Superfamily Ligands for Cancer Therapy. Cancers, 13(7), [1543].


Liu, B., Diaz Arguello, O. A., Chen, D., Chen, S., Saber, A., & Haisma, H. J. (2020). CRISPR-mediated ablation of overexpressed EGFR in combination with sunitinib significantly suppresses renal cell carcinoma proliferation. PLoS ONE, 15(5), [0232985].
van den Boom, N. A. C., Winters, M., Haisma, H. J., & Moen, M. H. (2020). Efficacy of Stem Cell Therapy for Tendon Disorders: A Systematic Review. Orthopaedic journal of sports medicine, 8(4).
Liu, B., Chen, D., Chen, S., Saber, A., & Haisma, H. (2020). Transcriptional activation of cyclin D1 via HER2/HER3 contributes to EGFR-TKI resistance in lung cancer. Biochemical Pharmacology, 178, [114095].


Saber, A., Liu, B., Ebrahimi, P., & Haisma, H. J. (2020). CRISPR/Cas9 for overcoming drug resistance in solid tumors. Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 28(1), 295-304.
Liu, B., Chen, S., Chen, D., Cao, F., Zwinderman, M., Kiemel, D., Aïssi, M., Dekker, F. J., Haisma, H. J., & La Rose, A. (2020). Inhibition of histone deacetylase 1 (HDAC1) and HDAC2 enhances CRISPR/Cas9 genome editing. Nucleic Acids Research, 48(2), 517-532.
de Boer, E. N., van der Wouden, P. E., Johansson, L. F., van Diemen, C. C., & Haisma, H. J. (2019). A next-generation sequencing method for gene doping detection that distinguishes low levels of plasmid DNA against a background of genomic DNA. Gene Therapy, 26(7-8), 338-346.
Liu, B., Saber, A., & Haisma, H. J. (2019). CRISPR/Cas9: A powerful tool for identification of new targets for cancer treatment. Drug Discovery Today, 24(4), 955-970.
Liu, B., Song, S., Setroikromo, R., Chen, S., Hu, W., Chen, D., van der Wekken, A. J., Melgert, B. N., Timens, W., van den Berg, A., Saber, A., & Haisma, H. J. (2019). CX Chemokine Receptor 7 Contributes to Survival of KRAS-Mutant Non-Small Cell Lung Cancer upon Loss of Epidermal Growth Factor Receptor. Cancers, 11(4), [455].
Zhang, B., Liu, B., Chen, D., Setroikromo, R., Haisma, H. J., & Quax, W. J. (2019). Histone Deacetylase Inhibitors Sensitize TRAIL-Induced Apoptosis in Colon Cancer Cells. Cancers, 11(5), [645].


Bosch, van den, T., Leus, N. G. J., Wapenaar, H., Boichenko, A., Hermans, J., Bischoff, R., Haisma, H. J., & Dekker, F. J. (2017). A 6-alkylsalicylate histone acetyltransferase inhibitor inhibits histone acetylation and pro-inflammatory gene expression in murine precision-cut lung slices. Pulmonary Pharmacology & Therapeutics, 44, 88-95.
Leus, N. G. J., van den Bosch, T., van der Wouden, P. E., Krist, K., Ourailidou, M. E., Eleftheriadis, N., Kistemaker, L. E. M., Bos, S., Gjaltema, R. A. F., Mekonnen, S. A., Bischoff, R., Gosens, R., Haisma, H. J., & Dekker, F. J. (2017). HDAC1-3 inhibitor MS-275 enhances IL10 expression in RAW264.7 macrophages and reduces cigarette smoke-induced airway inflammation in mice. Scientific Reports, 7, [45047].
Pas, H. I. M. F. L., Moen, M. H., Haisma, H. J., & Winters, M. (2017). No evidence for the use of stem cell therapy for tendon disorders: a systematic review. British Journal of Sports Medicine, 51(13), 996-1004.
Pas, H. I. M. F. L., Winters, M., Haisma, H. J., Koenis, M. J. J., Tol, J. L., & Moen, M. H. (2017). Stem cell injections in knee osteoarthritis: a systematic review. British Journal of Sports Medicine, 51(15), 1125-1133.
Wapenaar, H., van den Bosch, T., Leus, N. G. J., van der Wouden, P. E., Eleftheriadis, N., Hermans, J., Hailu, G. S., Rotili, D., Mai, A., Domling, A., Bischoff, R., Haisma, H. J., & Dekker, F. J. (2017). The relevance of K-i calculation for bi-substrate enzymes illustrated by kinetic evaluation of a novel lysine (K) acetyltransferase 8 inhibitor. European Journal of Medicinal Chemistry, 136, 480-486.


Arabpour, M., Cool, R., Faber, K. N., Quax, W. J., & Haisma, H. J. (2017). Receptor-specific TRAIL as a means to achieve targeted elimination of activated hepatic stellate cells. Journal of Drug Targeting, 25(4), 360-369.
Haisma, H., & Schalekamp, T. (2016). Apothekersopleidingen klaar voor de toekomst: Domeinspecifiek referentiekader en Raamplan Farmacie geven onderwijs richting. Pharmaceutisch Weekblad, 151(24), 18-19.
Haisma, H., & Schalekamp, T. (2016, May 10). Domeinspecifiek referentiekader & Raam plan Farmacie 2016.
Leus, N. G. J., van der Wouden, P. E., van den Bosch, T., Hooghiemstra, W. T. R., Ourailidou, M. E., Kistemaker, L. E. M., Bischoff, R., Gosens, R., Haisma, H. J., & Dekker, F. J. (2016). HDAC 3-selective inhibitor RGFP966 demonstrates anti-inflammatory properties in RAW 264.7 macrophages and mouse precision-cut lung slices by attenuating NF-κB p65 transcriptional activity. Biochemical Pharmacology, 58-74.
Haisma, H. (2016). Nederlands farmaceutisch onderwijs wereldwijd voorop. Pharmaceutisch Weekblad, 151(50), 21.
van den Bosch, T., Boichenko, A., Leus, N. G. J., Ourailidou, M. E., Wapenaar, H., Rotili, D., Mai, A., Imhof, A., Bischoff, R., Haisma, H. J., & Dekker, F. J. (2016). The histone acetyltransferase p300 inhibitor C646 reduces pro-inflammatory gene expression and inhibits histone deacetylases. Biochemical Pharmacology, 102, 130-140.


Haisma, H. (2014). Assessment of preclinical gene therapy studies worldwide. (3 ed.) COGEM.
Haisma, H. (2014). Sport: vliegensvlugge genen. In Genen en Gezondheid (Vol. Cahier 1). Stichting Biowetenschappen en Maatschappij.
Arabpour, M., Poelstra, K., Helfrich, W., Bremer, E., & Haisma, H. J. (2014). Targeted elimination of activated hepatic stellate cells by an anti-epidermal growth factor-receptor single chain fragment variable antibody-tumor necrosis factor-related apoptosis-inducing ligand (scFv425-sTRAIL). Journal of gene medicine, 16(9-10), 281-290.
Arabpour, M., Poelstra, K., Helfrich, W., Bremer, E., & Haisma, H. J. (2014). Targeted Elimination of Activated Hepatic Stellate Cells by Anti-EGF-Receptor scFv-sTRAIL Fusion Protein. Molecular Therapy, 22(suppl. 1), S121-S121.


Wisastra, R., Kok, P. A. M., Eleftheriadis, N., Baumgartner, M. P., Camacho, C. J., Haisma, H. J., & Dekker, F. J. (2013). Discovery of a novel activator of 5-lipoxygenase from an anacardic acid derived compound collection. Bioorganic & Medicinal Chemistry, 21(24), 7763-7778.
van der Gronde, T., de Hon, O., Haisma, H. J., & Pieters, T. (2013). Gene doping: An overview and current implications for athletes. British Journal of Sports Medicine, 47(11), 670-678.
van Dijk, R., Miranda, P. S. M., Riviere, C., ten Bloemendaal, L., van Gorp, J., Duijst, S., de Waart, D. R., Beuers, U., Haisma, H. J., & Bosma, P. J. (2013). Polyinosinic acid blocks adeno-associated virus macrophage endocytosis in vitro and enhances adeno-associated virus liver directed gene therapy in vivo. Human Gene Therapy, 24(12), A135.
van Dijk, R., Montenegro-Miranda, P. S., Riviere, C., Schilderink, R., ten Bloemendaal, L., van Gorp, J., Duijst, S., de Waart, D. R., Beuers, U., Haisma, H. J., & Bosma, P. J. (2013). Polyinosinic Acid Blocks Adeno-Associated Virus Macrophage Endocytosis In Vitro and Enhances Adeno-Associated Virus Liver-Directed Gene Therapy In Vivo. Human Gene Therapy, 24(9), 807-813.
Kuldo, J. M., Asgeirsdottir, S. A., Zwiers, P. J., Bellu, A. R., Rots, M. G., Schalk, J. A. C., Ogawara, K. I., Trautwein, C., Banas, B., Haisma, H. J., Molema, G., & Kamps, J. A. A. M. (2013). Targeted adenovirus mediated inhibition of NF-kappa B-dependent inflammatory gene expression in endothelial cells in vitro and in vivo. Journal of Controlled Release, 166(1), 57-65.


Wisastra, R., Ghizzoni, M., Boltjes, A., Haisma, H. J., & Dekker, F. J. (2012). Anacardic acid derived salicylates are inhibitors or activators of lipoxygenases. Bioorganic & Medicinal Chemistry, 20(16), 5027-5032.
Farinha Antunes, I., Doorduin, J., Haisma, H. J., Elsinga, P. H., van Waarde, A., Willemsen, A. T. M., Dierckx, R. A., & de Vries, E. F. J. (2012). F-18-FEAnGA for PET of beta-Glucuronidase Activity in Neuroinflammation. Journal of Nuclear Medicine, 53(3), 451-458.
Antunes, I. F., Haisma, H. J., Elsinga, P. H., Sijbesma, J. W. A., van Waarde, A., Willemsen, A. T. M., Dierckx, R. A., & de Vries, E. F. J. (2012). In vivo evaluation of [F-18]FEAnGA-Me: a PET tracer for imaging beta-glucuronidase (beta-GUS) activity in a tumor/inflammation rodent model. Nuclear Medicine and Biology, 39(6), 854-863.
Farinha Antunes, I., Haisma, H. J., Elsinga, P. H., van Waarde, A., Willemsen, A. T. M., Dierckx, R. A., & de Vries, E. F. J. (2012). In Vivo Evaluation of 1-O-(4-(2-Fluoroethyl-Carbamoyloxymethyl)-2-Nitrophenyl)-O-beta-D-Glucopyronuronate: A Positron Emission Tomographic Tracer for Imaging beta-Glucuronidase Activity in a Tumor/Inflammation Rodent Model. Molecular imaging, 11(1), 77-87.
Farinha Antunes, I., Haisma, H. J., Elsinga, P. H., Di Gialleonardo, V., van Waarde, A., Willemsen, A. T. M., Dierckx, R. A., & de Vries, E. F. J. (2012). Induction of beta-Glucuronidase Release by Cytostatic Agents in Small Tumors. Molecular pharmaceutics, 9(11), 3277-3285.
Haisma, H. J. (2012). Physical Enhancement. In J. Savulescu, R. ter Meulen, & G. Kahane (Eds.), Enhancing human capacities (pp. 257-265). Wiley-Blackwell.
Ghizzoni, M., Wu, J., Gao, T., Haisma, H. J., Dekker, F. J., & Zheng, Y. G. (2012). 6-alkylsalicylates are selective Tip60 inhibitors and target the acetyl-CoA binding site. European Journal of Medicinal Chemistry, 47(1), 337-344.


Wisastra, R., Poelstra, K., Bischoff, R., Maarsingh, H., Haisma, H. J., & Dekker, F. J. (2011). Antibody-Free Detection of Protein Tyrosine Nitration in Tissue Sections. ChemBioChem, 12(13), 2016-2020.
Varkouhi, A. K., Scholte, M., Storm, G., & Haisma, H. J. (2011). Endosomal escape pathways for delivery of biologicals. Journal of Controlled Release, 151(3), 220-228.
Ghizzoni, M., Haisma, H. J., Maarsingh, H., & Dekker, F. J. (2011). Histone acetyltransferases are crucial regulators in NF-kappa B mediated inflammation. Drug Discovery Today, 16(11-12), 504-511.
Wisastra, R., Ghizzoni, M., Maarsingh, H., Minnaard, A. J., Haisma, H. J., & Dekker, F. J. (2011). Isothiazolones; thiol-reactive inhibitors of cysteine protease cathepsin B and histone acetyltransferase PCAF. Organic and Biomolecular Chemistry, 9(6), 1817-1822.
Haisma, H. J., & Bellu, A. R. (2011). Pharmacological Interventions for Improving Adenovirus Usage in Gene Therapy. Molecular pharmaceutics, 8(1), 50-55.


van Zeeburg, H. J. T., van Beusechem, V. W., Huizenga, A., Haisma, H. J., Korokhov, N., Gibbs, S., Leemans, C. R., & Brakenhoff, R. H. (2010). Adenovirus retargeting to surface expressed antigens on oral mucosa. Journal of gene medicine, 12(4), 365-376.
Ghizzoni, M., Boltjes, A., de Graaf, C., Haisma, H. J., & Dekker, F. J. (2010). Improved inhibition of the histone acetyltransferase PCAF by an anacardic acid derivative. Bioorganic & Medicinal Chemistry, 18(16), 5826-5834.
Haisma, H. J., Kamps, G. K., Bouma, A., Geel, T. M., Rots, M. G., Kariath, A., & Bellu, A. R. (2010). Selective targeting of adenovirus to alpha(v)beta(3) integrins, VEGFR2 and Tie2 endothelial receptors by angio-adenobodies. International Journal of Pharmaceutics, 391(1-2), 155-161.
Farinha Antunes, I., Haisma, H. J., Elsinga, P. H., Dierckx, R. A., & de Vries, E. F. J. (2010). Synthesis and Evaluation of [F-18]-FEAnGA as a PET Tracer for beta-Glucuronidase Activity. BIOCONJUGATE CHEMISTRY, 21(5), 911-920.


Aben, R. W. M., de Vos, D., Haisma, H. J., Cornelissen, J. J. L. M., & Scheeren, J. W. (2009, Mar 1). Esters of glucuronide prodrugs of anthracyclines and method of preparation and use in tumor-selective chemotherapy. Google Patents.
Dekker, F. J., & Haisma, H. J. (2009). Histone acetyl transferases as emerging drug targets. Drug Discovery Today, 14(19-20), 942-948.
Dekker, F. J., Ghizzoni, M., van der Meer, N., Wisastra, R., & Haisma, H. J. (2009). Inhibition of the PCAF histone acetyl transferase and cell proliferation by isothiazolones. Bioorganic & Medicinal Chemistry, 17(2), 460-466.
Ghizzoni, M., Haisma, H. J., & Dekker, F. J. (2009). Reactivity of isothiazolones and isothiazolone-1-oxides in the inhibition of the PCAF histone acetyltransferase. European Journal of Medicinal Chemistry, 44(12), 4855-4861.
Haisma, H. J., Boesjes, M., Beerens, A. M., van der Strate, B. W. A., Curiel, D. T., Plueddemann, A., Gordon, S., & Bellu, A. R. (2009). Scavenger Receptor A: A New Route for Adenovirus 5. Molecular pharmaceutics, 6(2), 366-374.


Riezebos-Brilman, A., Walczak, M., Regts, J., Rots, M. G., Kamps, G., Dontje, B., Haisma, H. Y., Wilschut, J., & Daemen, T. (2008). A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer (vol 14, pg 1695, 2007). Gene Therapy, 15(1), 66.
Johnson, T. S., Mahnke, K., Storn, V., Schoenfeld, K., Ring, S., Nettelbeck, D. M., Haisma, H. J., Le Gall, F., Kontermann, R. E., & Enk, A. H. (2008). Inhibition of Melanoma Growth by Targeting of Antigen to Dendritic Cells via an Anti-DEC-205 Single-Chain Fragment Variable Molecule. Clinical Cancer Research, 14(24), 8169-8177.
Schoemaker, M. H., Rots, M. G., Beljaars, L., Ypma, A. Y., Jansen, P. L. M., Poelstra, K., Moshage, A., & Haisma, H. J. (2008). PDGF-receptor beta-targeted adenovirus redirects gene transfer from hepatocytes to activated stellate cells. Molecular pharmaceutics, 5(3), 399-406.
Haisma, H. J., Kamps, J. A. A. M., Plantinga, J. A., Rots, M. G., Bellu, A. R., & Kamps, G. (2008). Polyinosinic acid enhances delivery of adenovirus vectors in vivo by preventing sequestration in liver macrophages. Journal of general virology, 89, 1097-1105.
Bremer, E., van Dam, G. M., de Bruyn, M., van Riezen, M., Dijkstra, M., Kamps, G., Helfrich, W., & Haisma, H. (2008). Potent Systemic Anticancer Activity of Adenovirally Expressed EGFR-Selective TRAIL Fusion Protein. Molecular Therapy, 16(12), 1919-1926.
Beerens, A. M. J., Rots, M. G., Bermudez, B., De Vries, E. F. J., & Haisma, H. J. (2008). Secretion of thymidine kinase to increase the effectivity of suicide gene therapy results in the loss of enzymatic activity. Journal of Drug Targeting, 16(1), 26-35.
Farinha Antunes, I., Haisma, H. J., & de Vries, E. F. J. (2008). Tumor-specific activation of prodrugs: Is there a role for nuclear medicine? Nuclear Medicine Communications, 29(10), 845-846.


Riezebos-Brilman, A., Walczak, M., Regts, J., Rots, M., Kamps, G., Dontje, B., Haisma, H., Wilschut, J., & Daemen, T. (2007). A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer. Gene Therapy, 14(24), 1695-1704.
Carette, J. E., Graat, H. C. A., Schagen, F. H. E., Mastenbroek, D. C. J., Rots, M. G., Haisma, H. J., Groothuis, G. M. M., Schaap, G. R., Bras, J., Kaspers, G. J. L., Wuisman, P. I. J. M., Gerritsen, W. R., & van Beusechem, V. W. (2007). A conditionally replicating adenovirus with strict selectivity in killing cells expressing epidermal growth factor receptor. Virology, 361(1), 56-67.
Gommans, W. M., McLaughlin, P. M. J., Lindhout, B. I., Segal, D. J., Wiegman, D. J., Haisma, H. J., van der Zaal, B. J., & Rots, M. G. (2007). Engineering zinc finger protein transcription factors to downregulate the epithelial glycoprotein-2 promoter as a novel anti-cancer treatment. Molecular carcinogenesis, 46(5), 391-401.
Beerens, A. M. J., Rots, M. G., de Vries, E. F. J., & Haisma, H. J. (2007). Fusion of herpes simplex virus thymidine kinase to VP22 does not result in intercellular trafficking of the protein. International journal of molecular medicine, 19(5), 841-849.
Gommans, W. M., McLaughlin, P. M. J., Schalk, J. A. C., Groothuis, G. M. M., Haisma, H. J., & Rots, M. G. (2007). Highly efficient and carcinoma-specific adenoviral replication restricted by the EGP-2 promoter. Journal of Controlled Release, 117(1), 1-10.


Rots, MG., Elferink, MGL., Gommans, WM., Oosterhuis, D., Schalk, JAC., Curiel, DT., Olinga, P., Haisma, HJ., & Groothuis, GMM. (2006). An ex vivo human model system to evaluate specificity of replicating and non-replicating gene therapy agents. Journal of gene medicine, 8(1), 35-41.
Stoff-Khalili, M. A., Rivera, A. A., Le, L. P., Stoff, A., Everts, M., Contreras, J. L., Chen, D., Teng, L., Rots, M. G., Haisma, H. J., Rocconi, R. P., Bauerschmitz, G. J., Rein, D. T., Yamamoto, M., Siegal, G. P., Dall, P., Michael Mathis, J., & Curiel, D. T. (2006). Employment of liver tissue slice analysis to assay hepatotoxicity linked to replicative and nonreplicative adenoviral agents. Cancer Gene Therapy, 13(6), 606-618.
Ogawara, K., Kuldo, JM., Oosterhuis, K., Kroesen, BJ., Rots, MG., Trautwein, C., Kimura, T., Haisma, HJ., & Molema, G. (2006). Functional inhibition of NF-kappa B signal transduction in alpha v alpha beta 3 integrin expressing endothelial cells by using RGD-PEG-modified adenovirus with a mutant I kappa B gene. Arthritis Research and Therapy, 8(1), [32].
Haisma, HJ., & de Hon, O. (2006). Gene doping. International Journal of Sports Medicine, 27(4), 257-266.
Haisma, HJ., De Hon, O., Sollie, P., & Vorstenbosch, J. (2006). Genetische doping. Nederlands Tijdschrift voor Klinische Chemie en Laboratoriumgeneeskunde, 31(1), 19.
Karpanen, T., Wirzenius, M., Mäkinen, T., Veikkola, T., Haisma, H. J., Achen, M. G., Stacker, S. A., Pytowski, B., Ylä-Herttuala, S., & Alitalo, K. (2006). Lymphangiogenic growth factor responsiveness is modulated by postnatal lymphatic vessel maturation. American Journal of Pathology, 169(2), 708-718.
Mahasreshti, PJ., Kataram, M., Wu, HJ., Yalavarthy, LP., Carey, D., Dent, P., Chada, S., Alvarez, RD., Haisma, HJ., Fisher, PB., & Curiel, DT. (2006). Ovarian cancer targeted adenoviral-mediated mda-7/IL-24 gene therapy. Gynecologic Oncology, 100(3), 521-532.
Visser, A. E., Verschure, P. J., Gommans, W. M., Haisma, H. J., & Rots, M. G. (2006). Step into the Groove: Engineered Transcription Factors as Modulators of Gene Expression. In JC. Hall, JC. Dunlap, T. Friedmann, & VanHeyningen (Eds.), ADVANCES IN GENETICS (pp. 131-+). (Advances in Genetics; Vol. 56). Academic Press.
Gommans, WM., van Eert, SJ., McLaughlin, PMJ., Harmsen, MC., Yamamoto, M., Curiel, DT., Haisma, HJ., & Rots, MG. (2006). The carcinoma-specific epithelial glycoprotein-2 promoter controls efficient and selective gene expression in an adenoviral context. Cancer Gene Therapy, 13(2), 150-158.
Gommans, W. M., Oosterhuis, D., Dmitriev, I., Schaack, J., Curiel, D. T., Haisma, H. J., & Rots, M. G. (2006). Towards a double controlled conditionally replicative adenovirus for potent and specific melanoma cell kill. Journal of Controlled Release, 116(2), E64-E66.


Oosterhoff, D., Overmeer, RM., de Graaf, M., van der Meulen, IH., Giaccone, G., van Beusechem, VW., Haisma, HJ., Pinedo, HM., & Gerritsen, WR. (2005). Adenoviral vector-mediated expression of a gene encoding secreted, EpCAM-targeted carboxylesterase-2 sensitises colon cancer spheroids to CPT-11. British Jounal of Cancer, 92(5), 882-887.
Roy, H., Bhardwaj, S., Babu, M., Jauhiainen, S., Herzig, KH., Bellu, AR., Haisma, HJ., Carmeliet, P., Alitalo, K., & Yla-Herttuala, S. (2005). Adenovirus-mediated gene transfer of placental growth factor to perivascular tissue induces angiogenesis via upregulation of the expression of endogenous vascular endothelial growth factor-A. Human Gene Therapy, 16(12), 1422-1428.
Gommans, WM., Haisma, HJ., & Rots, MG. (2005). Engineering zinc finger protein transcription factors: The therapeutic relevance of switching endogenous gene expression on or off at command. Journal of Molecular Biology, 354(3), 507-519.
Lu, B., Makhija, SK., Nettelbeck, DM., Rivera, AA., Komarova, S., Zhou, F., Yamamoto, M., Haisma, HJ., Alvarez, RD., Curiel, DT., & Zhu, ZB. (2005). Evaluation of tumor-specific promoter activities in melanoma. Gene Therapy, 12(4), 330-338.
Kraaij, R., van Rijswijk, ALCT., Haisma, HJ., & Bangma, CH. (2005). Prostate specific membrane antigen (PSMA) is a tissue-specific target for adenoviral transduction of prostate cancer in vitro. Prostate, 62(3), 253-259.
Buursma, A. R., Beerens, A., de Vries, E. F. J., van Waarde, A., Rots, M., Hospers, G. A. P., Vaalburg, W., & Haisma, H. J. (2005). The human norepinephrine transporter in combination with C-11-m-hydroxyephedrine as a reporter gene/reporter probe for PET of gene therapy. Journal of Nuclear Medicine, 46(12), 2068-2075.
Haisma, H. J., & de Hon, O. (2005). Ziek, beter, best: van gentherapie tot genetische doping. In Beter dan Goed, over Genetica en de toekomst van Topsport (pp. 120 - 137). Veen Magazines B.V..


Nevalainen, T. J., Scheeren, H. W., Pinedo, H. M., Haisma, H. J., & Boven, E. (2004). A methylester of the glucuronide prodrug DOX-GA3 for improvement of tumor-selective chemotherapy. Biochemical Pharmacology, 68(11), 2273-2281.
Kirby, TO., Rivera, A., Rein, D., Ulasov, N. V., Breidenbach, M., Kataram, M., Contreras, JL., Krumdieck, C., Yamamoto, M., Rots, MG., Haisma, HJ., Alvarez, RD., Mahasreshti, PJ., & Curiel, DT. (2004). A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity. Clin.Cancer Res., 10(24), 8697 - 8703.
Ogawara, K., Rots, M., Kok, R. J., Moorlag, H. E., van Loenen - Weemaes, A., Meijer, D. K. F., Haisma, H. J., & Molema, I. (2004). A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo. Human Gene Therapy, 15(5), 433 - 443.
Rots, M., Gommans, W. M., Dmitriev, I., Oosterhuis, D., Seki, T., Curiel, D. T., & Haisma, H. J. (2004). A platform for constucting infectivity-enhanced fiber-mosaic adenoviruses genetically modified to express two fiber types. Gene Therapy and Molecular Biology, 8, 1 - 8.
Leath, CA., Kataram, M., Bhagavatula, P., Gopalkrishnan, RV., Dent, P., Fisher, PB., Pereboev, A., Carey, D., Lebedeva, N. V., Haisma, HJ., Alvarez, RD., Curiel, DT., & Mahasreshti, PJ. (2004). Infectivity enhanced adenoviral-mediated mda-7/IL-24 gene therapy for ovarian carcinoma. Gynecologic Oncology, 94(2), 352 - 362.
Pinedo, H. M., Oosterhoff, D., Van der Meulen-Muileman, I. H., Gerritsen, W. R., Haisma, H. J., & Boven, E. (2004). Pronounced antitumor efficacy by extracellular activation of a doxorubicin-glucuronide prodrug after adenoviral vector-mediated expression of a human antibody-enzyme fusion protein. Human Gene Therapy, 15(3), 229 - 238.
Schoemaker, M., Conde de la Rosa, L., Buist-Homan, M., Vrenken, T. E., Havinga, R., Poelstra, K., Haisma, H. J., Jansen, P. LM., & Moshage, A. J. H. (2004). Tauroursodeoxycholic acid protects rat hepatocytes from bile acid-induced apoptosis via activation of survival pathways. Hepatology, 39(6), 1563 - 1573.


Brandao, JG., Scheper, RJ., Lougheed, SM., Curiel, DT., Tillman, BW., Gerritsen, WR., van den Eertwegh, AJM., Pinedo, HM., Haisma, HJ., & de Gruijl, TD. (2003). CD40-targeted adenoviral gene transfer to dendritic cells through the use of a novel bispecific single-chain Fv antibody enhances cytotoxic T cell activation. Vaccine, 21(19-20), 2268-2272.
van Beusechem, V. W., Mastenbroek, D. C., Van den Doel, P. B., Lamfers, M. L., Grill, J., Wurdinger, T., Haisma, H. J., Pinedo, H. M., & Gerritsen, W. R. (2003). Conditionally replicative adenovirus expressing a targeting adapter molecule exhibits enhanced oncolytic potency on CAR-deficient tumors. Gene Therapy, 10(23), 1982-1991.
Pinedo, H. M., Quadir, R., Haisma, H. J., & Boven, E. (2003). Cytosolic beta-glycosidases for activation of glycoside prodrugs of daunorubicin. Biochem.Pharmacol., 65(11), 1875-1881.
Oosterhoff, D., Witlox, M. A., van Beusechem, V. W., Haisma, H. J., Schaap, G. R., Bras, J., Kruyt, W., Molenaar, B., Boven, E., Wuisman, P. I., Pinedo, H. M., & Gerritsen, W. R. (2003). Gene-directed enzyme prodrug therapy for osteosarcoma: Sensitization to CPT-11 in vitro and in vivo by adenoviral delivery of a gene encoding secreted carboxylesterase-2. Mol.Cancer Ther., 2(8), 765-771.
Mahasreshti, P. J., Kataram, M., Wang, M. H., Stockard, C. R., Grizzle, W. E., Carey, D., Siegal, G. P., Haisma, H. J., Alvarez, R. D., & Curiel, D. T. (2003). Intravenous delivery of adenovirus-mediated soluble FLT-1 results in liver toxicity. Clin.Cancer Res., 9(7), 2701 - 2710.
Fonseca, M. J., Jagtenberg, J. C., Haisma, H. J., & Storm, G. (2003). Liposome-mediated targeting of enzymes to cancer cells for site-specific activation of prodrugs: Comparison with the corresponding antibody-enzyme conjugate. Pharmaceutical Research, 20(3), 423-428.
Beerens, A. M., Al Hadithy, A. F., Rots, M., & Haisma, H. J. (2003). Protein transduction domains and their utility in gene therapy. Curr.Gene Ther., 3(5), 486 - 494.
Schoemaker, M., Gommans, W. M., Conde de la Rosa, L., Buist-Homan, M., Klok, P., Trautwein, C., van Goor, H., Poelstra, K., Haisma, H. J., Jansen, P. LM., & Moshage, A. J. H. (2003). Resistance of rat hepatocytes against bile acid-induced apoptosis in cholestatic liver injury is due to nuclear factor-kappa B activation. Journal of Hepatology, 39(2), 153-161.
Haisma, HJ., & Rots, MG. (2003). State of the art in gene therapy. In CTS. Sibinga, & LFM. DeLeij (Eds.), CELLULAR ENGINEERING AND CELLULAR THERAPIES (pp. 171-187). (DEVELOPMENTS IN HEMATOLOGY AND IMMUNOLOGY; Vol. 38). Springer.
Rots, MG., Curiel, DT., Gerritsen, WR., & Haisma, HJ. (2003). Targeted cancer gene therapy: the flexibility of adenoviral gene therapy vectors. J.Control Release, 87(1-3), 159-165.
Bruell, D., Stocker, M., Huhn, M., Redding, N., Kupper, M., Schumacher, P., Paetz, A., Bruns, CJ., Haisma, HJ., Fischer, R., Finnern, R., & Barth, S. (2003). The recombinant anti-EGF receptor immunotoxin 425(scFv)-ETA' suppresses growth of a highly metastatic pancreatic carcinoma cell line. Int.J.Oncol., 23(4), 1179-1186.
Uil, T. G., Haisma, H. J., & Rots, M. (2003). Therapeutic modulation of endogenous gene function by agents with designed DNA-sequence specificities. Nucleic Acids Res., 31(21), 6064-6078.
Last modified:21 December 2020 10.44 a.m.
printView this page in: Nederlands